StoneX Group’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

StoneX Group’s Portfolio CRXT Stock Details CRXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,685	Closed	-$4.46K	–	586
2022 Q2	$4.46K	Buy	+11,685	New	+$8.18K	﹤0.01%	482

Other funds holding CRXT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

StoneX Group's CRXT Position: Q3 2022 in Review

StoneX Group sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 11,685 shares — an estimated $4.46K sold.

StoneX Group first reported a position in CRXT in Q2 2022 and held it in 1 quarter. The position peaked at $4.46K in Q2 2022. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

StoneX Group reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
StoneX Group sold 11,685 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $4.46K.
StoneX Group first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
StoneX Group's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $4.46K in Q2 2022.
2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on StoneX Group's 13F filing for Q3 2022, filed 8 Nov 2022.